Fig. 1

β-catenin suppressed cells apoptosis and growth inhibition induced by sorafenib treatment in HCC cell lines. a. SMMC-7721 cells were transfected with adenovirus for control or overexpressing β-catenin. 24 h after transfection cells were treated with sorafenib (5 μM) for another 24 h. Cells were collected for western blotting assay. b. MHCC-97H cells were transfected with siRNA for scramble or β-catenin for 24 h and sorafenib (7.5 μM) treatment for another 24 h before western blotting assay. c. CCK-8 assays were performed to detect the growth inhibition of sorafenib on SMMC-7721 (upper panel) and MHCC-97H (bottom panel) with ADV-β-catenin or si-β-catenin. d, e. (Left panels) SMMC-7721 and MHCC-97H cells with overexpressing or silencing β-catenin were treated with sorafenib and cells were analyzed by flow cytometry. (Right panels) Columns, representing the total percentage of Q2 and Q4, were the average of three independent experiments. f, g. Dose-dependent effects of sorafenib on the viability of SMMC-7721 (f) and MHCC-97H (g) with ADV-β-catenin or si-β-catenin. Data were presented as mean ± SEM, ns, no significance; *P<0.05; **P<0.01; ***P<0.001